- Home
- PCRX vs DEA Comparison
PCRX vs DEA Comparison
Compare PCRX & DEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- DEA
- Stock Information
- Founded
- PCRX 2006
- DEA 2011
- Country
- PCRX United States
- DEA United States
- Employees
- PCRX N/A
- DEA N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- DEA Real Estate Investment Trusts
- Sector
- PCRX Health Care
- DEA Real Estate
- Exchange
- PCRX Nasdaq
- DEA Nasdaq
- Market Cap
- PCRX 1.2B
- DEA 998.2M
- IPO Year
- PCRX 2011
- DEA 2015
- Fundamental
- Price
- PCRX $23.96
- DEA $22.11
- Analyst Decision
- PCRX Strong Buy
- DEA Buy
- Analyst Count
- PCRX 6
- DEA 6
- Target Price
- PCRX $33.83
- DEA $24.99
- AVG Volume (30 Days)
- PCRX 769.6K
- DEA 556.6K
- Earning Date
- PCRX 11-06-2025
- DEA 10-27-2025
- Dividend Yield
- PCRX N/A
- DEA 8.21%
- EPS Growth
- PCRX N/A
- DEA N/A
- EPS
- PCRX 0.47
- DEA 0.30
- Revenue
- PCRX $716,791,000.00
- DEA $334,212,000.00
- Revenue This Year
- PCRX $7.27
- DEA $9.45
- Revenue Next Year
- PCRX $10.18
- DEA $7.37
- P/E Ratio
- PCRX $50.52
- DEA $73.69
- Revenue Growth
- PCRX 3.14
- DEA 10.62
- 52 Week Low
- PCRX $16.29
- DEA $19.33
- 52 Week High
- PCRX $27.64
- DEA $31.55
- Technical
- Relative Strength Index (RSI)
- PCRX 56.14
- DEA 57.89
- Support Level
- PCRX $22.29
- DEA $20.56
- Resistance Level
- PCRX $24.95
- DEA $22.18
- Average True Range (ATR)
- PCRX 1.23
- DEA 0.55
- MACD
- PCRX 0.09
- DEA 0.11
- Stochastic Oscillator
- PCRX 78.19
- DEA 95.28
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.